![Class_IV_b](http://rebiolup.com/wp-content/uploads/2020/07/Class_IV_b.png)
A prospective repeat kidney biopsy endeavour
![line](http://rebiolup.com/wp-content/uploads/2020/07/line.jpg)
This study is conducted within the frame of the Lupus Nephritis Trials Network, and is endorsed by the European Lupus Society (SLEuro) and the European Renal Association (ERA).
Objectives
![a](http://rebiolup.com/wp-content/uploads/2020/07/a-1.png)
to determine
the percentage of LN patients in histopathological remission after 12 months of standard of care immunosuppression.
![b](http://rebiolup.com/wp-content/uploads/2020/07/b.png)
to correlate
histological and immunological response to therapy (immune deposits) with clinical response.
![c](http://rebiolup.com/wp-content/uploads/2020/07/c.png)
to evaluate
whether therapeutic decisions steered by the results of a per-protocol repeat kidney biopsy improve renal outcomes compared with a matched control group of patients who did not undergo repeat kidney biopsy.
![d](http://rebiolup.com/wp-content/uploads/2020/07/d-1.png)
to generate data
on how to evaluate response to therapy in pure membranous LN (ISN/RPS class V), as well as the value of the information retrieved from repeat kidney biopsies in portending long-term renal prognosis in this LN subset.
Steering Committee
![line](http://rebiolup.com/wp-content/uploads/2020/07/line.jpg)
Ioannis Parodis (Stockholm, Sweden)
Farah Tamirou (Brussels, Belgium)
Julia Weinmann-Menke (Mainz, Germany)
Hans-Joachim Anders (Munich, Germany)
Brad H. Rovin (Columbus, United States)
Frédéric A. Houssiau (Brussels, Belgium)